MedTrace Logo

Comparing Standard Platelet-Rich Plasma and Light-Enhanced Platelet-Rich Plasma for Treating Hair Loss in Androgenetic Alopecia: A Randomized Controlled Trial

NCT07739147 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-07-31

No results posted yet for this study

Summary

The goal of this clinical trial is to compare 3 different types of PRP in androgenetic alopecia patients. The main questions it aims to answer:

Does Redlight enhanced, Blue light enhanced, or traditional PRP result in higher hair density and health? Does Redlight enhanced, Blue light enhanced, or traditional PRP result in other improved hair metrics.

Participants will consent to a PRP treatment but will be blinded to the type. They will then be asked to return for Tricholab analysis at set post-operative timepoints to record changes in hair metrics (Baseline, 1 month, 3 months, 6 months, 9 months, 12 months).

Conditions

Interventions

DRUG

Platelet-Rich Plasma (PRP) Injections

Autologous platelet-rich plasma prepared from the participant's own peripherally drawn. Blood is processed via centrifugation to concentrate platelets and associated growth factors, then injected into the scalp across the area of hair thinning. Administered at each treatment visit per the study treatment schedule.

DEVICE

Red-light photobiomodulation with cooling

Standard Intervention 1 with PRP undergoing additional Stimulus 1: 620 nm, 1 J/cm², 10 minutes; Stimulus 2: 4°C cooling, 15 minutes via MetaCell Technologies System.

DEVICE

Blue-light photobiomodulation

Standard Intervention 1 with PRP undergoing additional Stimulus 1: 467 nm, 1 J/cm², 10 minutes; Stimulus 2: 37°C, 10 minutes using MetaCell Technologies System.

Sponsors & Collaborators

  • Kimberly Meathrel

    lead INDUSTRY

Principal Investigators

  • Kimberly Meathrel · Bespoke Skin MD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-12-30
Primary Completion
2027-12-30
Completion
2027-12-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07739147 on ClinicalTrials.gov